Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent roche compounds

ChemMedChem

Volumn 4, Issue 4, 2009, Pages 680-686

  Peters, Jens Uwe ^a   Schnider, Patrick ^a   Mattei, Patrizio ^a   Kansy, Manfred ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug discovery; Molecular properties polypharmacology; Promiscuity; Safety pharmacology

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TARGETING; PH; PRIORITY JOURNAL;

DRUG DISCOVERY; DRUG INDUSTRY; HYDROPHOBICITY; IONS; LIPIDS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SUBSTRATE SPECIFICITY;

EID: 65549132575     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800411     Document Type: Article

References (40)

1. M. Bauer, H.-J. Moller, E. Schneider, Expert Opin. Pharmacother. 2006, 7, 421-427.
2. B. L Roth, D. J. Sheffler, W. K. Kroeze, Nat. Rev. Drug Discovery 2004, 3, 353-359.
3. T. Hampton, JAMA J. Am. Med. Assoc. 2004, 292, 419-422.
4. L Abenhaim, Y. Moride, F. Brenot, S. Rich, J. Benichou, X. Kurz, T. Hi-genbottam, C. Oakley, E. Wouters, M. Aubier, G. Simonneau, B. Bégaud, N. Engl. J. Med. 1996, 335, 609-616;
5. E.J. Mark, E. D. Patalas, H. T. Chang, R. J. Evans, S. C. Kessler, N. Engl. J. Med. 1997, 337, 602-606;
6. W. Ni, M. W. Li, K. Thakali, D. Gregory, S. W. Watts, J. Pharmacol. Exp. Ther. 2004, 309, 845-852.
7. H. M. Connolly, J. L. Crary, M. D. McGoon, D. D. Hensrud, B. S. Edwards, W. D. Edwards, H. V. Schaff, W. Engl. J. Med. 1997, 337, 581-588.
8. S. Whitebread, J. Hamon, D. Bojanic, L. Urban, Drug Discovery Today 2005, 10, 1421-1433.
9. A. Bender, J. Scheiber, M. Glick, J. W. Davies, K. Azzaoui, J. Hamon, L. Urban, S. Whitebread, J. L. Jenkins, Chem Med Chem 2007, 2, 861-873.
10. K. Azzaoui, J. Hamon, B. Faller, S. Whitebread, E. Jacoby, A. Bender, J. L. Jenkins, L. Urban, Chem Med Chem 2007, 2, 874-880.
11. A. L. Hopkins, C. R. Groom, Wot. Rev. Drug Discovery 2002, 1, 727-730.
12. J. Mestres, E. Gregori-Puigjané, S. Valverde, R. V. Solé, Nat. Biotechnol. 2008, 26, 983-984.
13. A. Hopkins, J. S. Mason, J. P. Overington, Curr. Opin. Struct. Biol. 2006; 16, 127-136.
14. P. D. Leeson, B. Springthorpe, Nat. Rev. Drug Discovery 2007, 6, 881-890;
15. http://www.nature.com/nrd/journal/v6/n11/extref/nrd2445-s3.pdf (Supplementary Information, Box S3).
16. G. A. Whitlock, P. V. Fish, MJ. Fray, A. Stobie, F. Wakenhut, Bioorg. Med. Chem. Lett. 2008, 18, 2896-2899.
17. C. M. Krejsa, D. Horvath, S. L. Rogalski, J. E. Penzotti, B. Mao, F. Barbosa, J. C. Migeon, Curr. Opin. Drug Discovery Dev. 2003, 6, 470-480.
18. O. Roche, G. Trube, J. Zuegge, P. Pflimlin, A. Alanine, G. Schneider, Chem Bio Chem 2002, 3, 455-459;
19. M. C. Sanguinetti, M. Tristan-Firouzi, Nat. Chem. Biol. 2006, 2, 463-469;
20. P. Hoffmann, B. Warner, J. Pharmacol. Toxicol. Methods 2006, 53, 87-105;
21. W. S. Redfern, L. Carlsson, A. S. Davis, W. G. Lynch, I. MacKenzie, S. Palethorpe, P. K. Siegl, I. Strang, A. T. Sullivan, R. Wallis, A. J. Camm, T. G. Hammond, Cardiovasc. Res. 2003, 58, 32-45.
22. R. J. Riley, K. Grime, Drug Discovery Today Technol. 2004, 1, 365-372;
23. J. M. Hutzler, D. M. Messing, L. C. Wienkers, Curr. Opin. Drug Discovery Dev. 2005, 8, 51-58;
24. J. H, Lin, A. Y. H. Lu, Clin. Pharmacokinet. 1998, 35, 361-390.
25. O. Roche, P. Schneider, J. Zuegge, W. Guba, M. Kansy, A. Alanìne, K. Bleicher, F. Danel, E. M. Gutknecht, M. Rogers-Evans, W. Neidhart, H. Stalder, M. Dillon, E. Sjogren, N. Fotouhi, P. Gillespie, R. Goodnow, W. Harris, P. Jones, M. Taniguchi, S. Tsujii, W. von der Saal, G. Zimmer-mann, G. Schneider, J. Med. Chem. 2002, 45, 137-142.
26. S. L. McGovern, B. K. Shoichet, J. Med. Chem. 2003, 46, 2895-2907;
27. S. L. McGovern, E. Caselli, N. Gri-gorieff, B. K. Shoichet, J. Med. Chem. 2002, 45, 1712-1722.
28. M. M. Hann, A. R. Leach, G, Harper, J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
29. E. Gregori-Puigjané, J. Mestres, Comb. Chem. High Throughput Screening 2008, 11, 669-676.
30. Solubility measurements were performed according to an in-house-de-veloped method to assess solubility from a 10mM DMSO stock solution. This method is similar to the classical thermodynamic shake-flask solubility assay, with the only difference that DMSO is removed at the beginning by an additional lyophilization step. Therefore, this assay is known as a lyophilized solubility assay (LYSA).
31. The comparison of positively charged compounds with neutral compounds might be misleading, as the former are intrinsically more soluble, and at the same time more promiscuous.
32. Neutral insoluble compounds tend to be even more promiscuous than neutral soluble compounds; this might be explained by the correlation of solubility and lipophilicity, and the connection between lipophilicity and promiscuity.
33. L. Di, E. H. Kerns, Drug Discovery Today 2006, 11, 446-451.
34. H. Fischer, M. Kansy, D. Bur, Chimia 2000, 54, 640-645.
35. MoKa is a commercially available tool trained with Roche internal measurement data: F. Milletti, L. Storchi, G. Sforna, G. Cruciani, Gabriele, J. Chem. Inf. Model. 2007, 47, 2172-2181.
36. Calculations were performed according to: A) M. Kansy, H. Fischer, H. van de Waterbeemd, Trends in QSAR and Molecular Modeling 94, (Ed.: F. Sanz), Prous, Barcelona 1995;
37. H. van de Waterbeemd, M. Kansy, B. Wagner, H. Fischer, Lipophilicity in Drug Action and Toxicology, (Eds.: V. Pliška, B. Testa, H. van de Waterbeemd), VCH, Weinheim 1996.
38. Measurements were performed according to an in-house-developed miniaturized method to measure the shake-flask octanol-water partition coefficient at pH 7.4 (log D).
39. Measurements were performed according to: M. Kansy, F. Senner, K. J. Gubernator, J. Med. Chem. 1998, 41, 1007-1010.
40. Measurements were performed according to: R.I. Allen, K.J. Box, J. Comer, C. Peake, K.Y. Tarn, J. Pharm. Biomed. Anal. 1998, 17, 699-712.